Accretion Pharmaceuticals Limited (NSE:ACCPL)

Market Cap	736.44M
Revenue (ttm)	826.43M +329.7%
Net Income	90.81M
EPS	9.82
Shares Out	11.12M
PE Ratio	6.74
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,400
Average Volume	13,680
Open	64.30
Previous Close	63.45
Day's Range	63.85 - 66.60
52-Week Range	53.80 - 102.50
Beta	n/a
RSI	48.58
Earnings Date	Jun 10, 2026

About Accretion Pharmaceuticals

Accretion Pharmaceuticals Limited engages in the manufacturing and marketing of pharmaceutical products in India. The company offers antibiotic, antibacterial, antifungal, anti-inflammatory, anti-spasmodic, antihistamine, antiallergy, anticough, anticold, antiulcer, gastrointestinal, antacid, anti-diabetic, cardiac, anti-hypertensive, psychotropic, memory enhancer, vitamins, supplements, and other products. It also provides external preparation, oral powder, effervescent formulation, and nutraceutical products, as well as formulations for brain...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 125
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ACCPL

Financial Performance

In fiscal year 2025, Accretion Pharmaceuticals's revenue was 573.76 million, an increase of 329.70% compared to the previous year's 133.53 million. Earnings were 67.94 million, an increase of 355.08%.